Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer-Reference-Cited by-同舟云学术

Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer

Published:2019-06-11 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Kunath Frank¹²,Jensen Katrin³,Pinart Mariona¹,Kahlmeyer Andreas¹,Schmidt Stefanie²,Price Carrie L⁴,Lieb Verena¹,Dahm Philipp⁵⁶

Affiliation:

1. University Hospital Erlangen; Department of Urology; Krankenhausstrasse 12 Erlangen Germany 91054

2. UroEvidence@Deutsche Gesellschaft für Urologie; Berlin Germany

3. Heidelberg University Hospital; Institute of Medical Biometry and Informatics; Marsilius-Arkaden Im Neuenheimer Feld 130.3, 12. OG Heidelberg Baden-Württemberg Germany 69120

4. Welch Medical Library, Johns Hopkins Medical Institutions; Clinical Informationist Services; 2024 E. Monument St. Baltimore Maryland USA 21287

5. Minneapolis VA Health Care System; Urology Section; One Veterans Drive Mail Code 112D Minneapolis Minnesota USA 55417

6. University of Minnesota; Department of Urology; 420 Delaware Street SE MMC 394 Minneapolis Minnesota USA 55455

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003506.pub2/epdf/full

Reference153 articles.

1. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up;Kurth;Urology,2009

2. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: Final results of European organisation for the research and treatment of cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial);Schröder;European Urology,2009

3. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: Results of European Organisation for the Research and Treatment of Cancer 30846 - A phase III study;Schröder;Journal of Urology,2004

4. Long term results of immediate versus deferred androgen deprivation in patients with no local treatment for T0-4 N0-2 M0 prostate cancer (EORTC 30891);Studer;Journal of Urology,2011

5. Which subgroups of patients with newly diagnosed T0-4 N0-2 mo prostate cancer not suitable for local treatment with curative intent (EORTC 30891) are at risk to die from prostate cancer and benefit from immediate androgen deprivation?;Studer;European Urology Supplements,2007

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a high-performance multi-probe droplet digital PCR assay for high-sensitivity detection of human papillomavirus circulating tumor DNA from plasma;Oral Oncology;2023-08

2. The prognostic value of androgen to PSA ratio in predictive modeling of prostate cancer;Medical Hypotheses;2023-07

3. Validity and Future of Primary Androgen Deprivation Therapy in Prostate Cancer. Integration in the Era of New Agents Targeting the Androgen Receptor;Archivos Españoles de Urología;2023

4. Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia;PharmacoEconomics;2022-06-27

5. Misconduct in research integrity: Assessment the quality of systematic reviews in Cochrane urological cancer review group;Türk Üroloji Dergisi/Turkish Journal of Urology;2021-10-04